Stryker shares tumble despite strong Q2 results and raised guidance
ORLANDO - Nutriband Inc. (NASDAQ: NTRB), a company specializing in transdermal pharmaceutical products and showing remarkable market momentum with a 202% return over the past year, has announced the acquisition of a trademark from the US Patent and Trademark Office for "Nutriband™," which is associated with its AVERSA™ technology platform. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 4.96x. The registration, granted on February 18, 2025, encompasses various research and development services in the pharmaceutical and biochemical fields.
The trademark is a crucial step for Nutriband as it continues to develop AVERSA™ Fentanyl, a fentanyl transdermal system designed to deter abuse. This system is the first of its kind under the AVERSA™ platform, which integrates aversive agents into patches to make the misuse of drugs like fentanyl unpleasant.
Nutriband has partnered with Kindeva Drug Delivery to scale up the manufacturing process for AVERSA™ Fentanyl, in anticipation of seeking FDA approval. Market analysis by Health Advances suggests that AVERSA™ Fentanyl could achieve peak annual sales of $80 million to $200 million in the U.S., indicating the potential market impact of the abuse deterrent technology. With a current market capitalization of $82.19 million and analyst price targets suggesting significant upside potential, InvestingPro analysis indicates the stock may be undervalued relative to its Fair Value.
The AVERSA™ technology is not only recognized in the United States but also has patents granted in multiple countries, including Europe, Japan, Korea, Russia, Canada, Mexico, and Australia. It aims to maintain the availability of essential medications to patients while improving safety profiles.
Nutriband’s focus on developing transdermal pharmaceutical products is underscored by its robust intellectual property portfolio and the advancement of its lead product, the abuse deterrent fentanyl patch.
The information in this article is based on a press release statement. Nutriband’s forward-looking statements are subject to various risks and uncertainties, including the development and regulatory approval of its products, which could cause actual results to differ materially from those anticipated. While the company operates with moderate debt levels and maintains strong liquidity, InvestingPro data reveals it is not yet profitable, with an EBITDA of -$5.75 million in the last twelve months. Subscribers to InvestingPro can access 8 additional key insights about Nutriband’s financial health and market position.
In other recent news, Nutriband Inc. has announced a partnership with Kindeva Drug Delivery to develop the Aversa™ Fentanyl patch, an abuse-deterrent transdermal system. This collaboration involves shared development costs and aims to address opioid abuse by incorporating Nutriband’s patented technology. Furthermore, Nutriband has secured a Notice of Allowance for a U.S. patent on its Aversa™ abuse deterrent technology, which strengthens its intellectual property portfolio. This patent is expected to bolster Nutriband’s position in the pharmaceutical sector, particularly in abuse-deterrent transdermal products.
At its recent Annual Meeting, Nutriband shareholders approved key proposals, including the election of directors and the amended stock option plan. Shareholders also ratified the engagement of Sadler, Gibb & Associates, LLC as the independent audit firm for 2024. In terms of market analysis, Noble Capital has initiated coverage on Nutriband with an Outperform rating and a price target of $13.00, reflecting optimism about the company’s upcoming Phase 1 clinical trial. The trial’s success could lead to a New Drug Application filing in late 2025, with potential drug approval by the second half of 2026. These developments highlight Nutriband’s ongoing efforts in innovation and strategic planning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.